Rigel Pharmaceuticals, Inc. (RIGL) P/E Ratio History
Historical price-to-earnings valuation from 2010 to 2026
Loading P/E history...
RIGL Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Rigel Pharmaceuticals, Inc. (RIGL) trades at a price-to-earnings ratio of 1.4x, with a stock price of $26.67 and trailing twelve-month earnings per share of $18.50.
The current P/E is 98% below its 5-year average of 65.5x. Over the past five years, RIGL's P/E has ranged from a low of 1.4x to a high of 284.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, RIGL trades at a 94% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, RIGL trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RIGL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RIGL P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 25.9 | 1.13Best | -25% | |
| $6B | 8.6Lowest | - | +264%Best | |
| $4B | 9.4 | - | +68% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
RIGL Historical P/E Data (2010–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $27.04 | $18.72 | 1.4x | -98% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $42.83 | $18.91 | 2.3x | -97% |
| FY2025 Q3 | $28.33 | $6.17 | 4.6x | -93% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $18.73 | $5.41 | 3.5x | -95% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $17.99 | $2.07 | 8.7x | -87% |
| FY2024 Q4 | $16.82 | $0.97 | 17.3x | -74% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $16.18 | $0.21 | 76.2x | +16% |
| FY2011 Q1 | $71.10 | $0.25 | 284.4x | +334% | |
| FY2010 Q4 | Fri Dec 31 2010 00:00:00 GM | $75.30 | $0.71 | 106.1x | +62% |
| FY2010 Q3 | $84.10 | $0.56 | 150.2x | +129% |
Average P/E for displayed period: 65.5x
See RIGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RIGL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RIGL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRIGL — Frequently Asked Questions
Quick answers to the most common questions about buying RIGL stock.
Is RIGL stock overvalued or undervalued?
RIGL trades at 1.4x P/E, below its 5-year average of 65.5x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does RIGL's valuation compare to peers?
Rigel Pharmaceuticals, Inc. P/E of 1.4x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is RIGL's PEG ratio?
RIGL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2010-2026.